Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/06—Fungi, e.g. yeasts
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics

Definitions

• the invention relates to an antifungal mixture with fungal organism Pythium oligandrum designed for fighting fungi including fungal diseases and bacteria.
• Fungi and fungal diseases are a problem of every society and especially fungal diseases of skin of both people and animals belong to frequently occurring diseases of people and animals. Such fungal diseases are even more serious because they are usually transmitted not only by a direct contact of the sick and the healthy but also through the objects, which were in contact with the source of infection.
• Such methods also include e.g. the application of the fungus Pythium oligandrum according to the document CZ 9883 U1 in the form of the biological preparation for fighting the origins of dermatophysis, which includes the said fungal organism in the form of oospora as the effective substance, when the total number of oospora is 2 ⁇ 10 5 in 1 g of the preparation as a maximum.
• this solution has a limited range of application and its effective substance is only bound on the inorganic carrier, which is silicon dioxide.
• Fungi from walls and fungi, yeast fungi and bacteria from various objects are removed by means of a series of different preparations, which are, however, never based on the application of the effective substance of the fungal organism Pythium oligandrum.
• the fungal organism Pythium oligandrum from the kingdom Chromista—Stramenopila is a strong mycoparasite; it parasites over 20 families of causative agents of fungal diseases and represents the dividing line between fungi and protozoa because of its sexual as well as asexual reproduction.
• the fibres of Pythium oligandrum penetrate the cells of the parasite (fungi, yeast fungi, bacteria) and draw the substances required for its own nutrition from them. On the basis of nutrition and spatial competition, it squeezes out the pathogens from the spaces.
• the nature of the activity of this fungus is, therefore, parasiting on fungi with the simultaneous production of enzymes, which further increase the efficiency of the fungus.
• Pythium oligandrum attacks the opponent with direct parasitism.
• Pythium oligandrum disappears from that locality (both human and animal bodies do not represent a natural environment for it and it cannot adapt to such environment) and it gives way for the re-settlement of the so-called normal micro-flora or, unless it finds new nutrition (fungi), it is encapsulated into dormancy conditions and its life cycle is paused.
• Pythium oligandrum can be used independently or in combination with other carriers (components) than silicon dioxide, which is also used according to the aforesaid applied design.
• the number of the reproduction organs of the fungal organism Pythium oligandrum according to this technical solution is higher than 2 ⁇ 10 5 in 1 g of the mixture.
• the weight expression it means that the mixture consists of 0.001 to 25 weight portions of Pythia oligandrum as a minimum and 75 to 99.999 weights portions of inert components.
• Pythium oligandrum also suppresses symptoms of other diseases than dermatophysis, namely also microbiological settlement of proboscis, other inflammations of buccal caxity, psoriasis, haemorrhoids, varicose ulcers, bed sores, “diabetic feet”, atopic eczema, acne, cold sores, sore spots, nail fungi, falling hair, dandruff or old-age itchiness.
• this solution can be newly used for suppressing mycotic infections and putrefactive processes on paws, cloven hoofs, hoofs, hair, skin, eyes, shells, in mouth, scales, mucous membranes and auditory passages of animals or in the body of animals.
• this new solution enables to use the mixture for the treatment of human diseases of fungal, bacterial or other origin on skin, mucous membranes, in the hair part or in the body of humans. Further to that, this solution enables to use the mixtures for animals against the diseases of fungal, bacterial or other origin on paws, cloven hoofs, hoofs, hair, skin, eyes, shells, in mouth, scales, mucous membranes and auditory passages of animals or in the body of animals.
• Another application is also the violation of bio-films on heterogeneous materials used both in human and veterinary medicine (artificial valves, joint replacements, contact lenses, catheters etc.).
• the technical solution also enables to eliminate microflora virtually from all objects, which come into contact with humans and animals, e.g. from interiors of the means of transport, seat furniture, animal cages etc.
• oligandrin Various inert carriers are used for the new mixtures in different ratios, which do not damage the microscopic fungus Pythium oligandrum (creation of the fungal fibres and characteristic echinate oospore, zoospore and zoosporangia) and producing various enzymes, which are collectively called oligandrin.
• Pythium oligandrum is used in various concentrations for these new mixtures, when the number of the reproductive organs of the fungal organism Pythium oligandrum is higher than 2 ⁇ 10 5 in 1 g of the mixture.
• the new inert components are especially biological organic and/or inorganic solutions, such as oil bases, physiological solutions, aromatic solutions, ointments, suppositories, pastes, creams, toothpastes, mouthwashes etc. Further to that, it concerns suspensions, emulsions or solid (loose) compositions of individual components, e.g. dusting powders, powders etc. or suspensions, emulsions or solutions from such individual substances.
• weight expression as stated above, it means that the mixture includes 0.001 to 25 weight portions of Pythium oligandrum and 75 to 99.999 weight portions of inert components.
• the activity of Pythium oligandrum in the mixture only arises after soaking or wetting e.g. also by skin, which is always sweating etc.
• the antifungal mixture with fungal organism Pythium oligandrum can be used both in human and veterinary medicine, in the cosmetic industry and also in households for maintaining cleanness and for elimination of fungi from walls of building objects and for violation of bio-films on heterogeneous materials and for elimination of microflora on objects coming in contact with humans or animals.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Mycology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Botany (AREA)
• Medical Informatics (AREA)
• Epidemiology (AREA)
• Alternative & Traditional Medicine (AREA)
• Pest Control & Pesticides (AREA)
• Communicable Diseases (AREA)
• Environmental Sciences (AREA)
• Wood Science & Technology (AREA)
• Dentistry (AREA)
• Agronomy & Crop Science (AREA)
• Oncology (AREA)
• Plant Pathology (AREA)
• Virology (AREA)
• Dermatology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=42289467

Family Applications (3)

Family Applications After (2)

Country Status (16)

Cited By (5)

Families Citing this family (6)

Citations (1)

Family Cites Families (7)

• 2009
  • 2009-11-04 CZ CZ20090724A patent/CZ2009724A3/cs unknown
  • 2009-12-14 UA UAA201206771A patent/UA107204C2/ru unknown
  • 2009-12-14 JP JP2012537295A patent/JP6053521B2/ja active Active
  • 2009-12-14 CN CN200980162343.5A patent/CN102655754B/zh active Active
  • 2009-12-14 EA EA201270615A patent/EA033217B1/ru not_active IP Right Cessation
  • 2009-12-14 EP EP09809019.4A patent/EP2496088B1/fr active Active
  • 2009-12-14 MX MX2012005278A patent/MX337150B/es active IP Right Grant
  • 2009-12-14 BR BR112012010689A patent/BR112012010689B8/pt active IP Right Grant
  • 2009-12-14 AU AU2009354904A patent/AU2009354904B2/en not_active Ceased
  • 2009-12-14 CA CA2779541A patent/CA2779541C/fr active Active
  • 2009-12-14 US US13/505,788 patent/US20120225035A1/en not_active Abandoned
  • 2009-12-14 WO PCT/CZ2009/000154 patent/WO2011054322A1/fr active Application Filing
• 2012
  • 2012-04-26 TN TNP2012000194A patent/TN2012000194A1/en unknown
  • 2012-05-01 IL IL219510A patent/IL219510A/en active IP Right Grant
  • 2012-05-14 ZA ZA2012/03481A patent/ZA201203481B/en unknown
  • 2012-05-17 MA MA34876A patent/MA33756B1/fr unknown
• 2014
  • 2014-01-10 US US14/152,554 patent/US9084750B2/en active Active
• 2015
  • 2015-06-10 US US14/735,347 patent/US20150313953A1/en not_active Abandoned
• 2016
  • 2016-08-29 JP JP2016166810A patent/JP2017019832A/ja active Pending

Patent Citations (1)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events